I never said they where driven by American revenue alone, I said it was a disproportionate amount of the profits and thus incentive.
5% of the people (actually a bit less but 5% will do) in the US, and (according to states someone else used here I didn't confirm it) 49% of the revenue.
Of course many people are much poorer, but Europe has more people than the US but is a much smaller source of revenue.
It has nothing to do with "poor American drug companies". They do ok (even if not as well as many think when you consider startups and smaller companies that fail). The issue is not "Oh the drug companies are suffering", or "How can we help them?". The issue is that they, like most people or organizations, respond to incentives. Reduce the profitability of drugs by a great amount, by political pressure, price controls, monopsony buyers, etc. and you get less new drug development.
I really do think that many believe that drugs are mostly developed in the US.
Perhaps many people believe that, but no one here is arguing that, so its irrelevant to this conversation. There are lots of false beliefs in the world, but most of them have nothing to do with the conversation here. |
